Icon Plc ( (ICLR) ) has released its Q2 earnings. Here is a breakdown of the information Icon Plc presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
ICON plc, headquartered in Dublin, Ireland, is a prominent clinical research organization that provides outsourced services to pharmaceutical, biotechnology, medical device, and government and public health organizations worldwide. The company is renowned for its innovative solutions in advancing clinical research from molecule to medicine.
In its second quarter of 2025, ICON plc reported gross business wins of $2,966 million, marking a 10.6% increase from the first quarter. The company’s net income rose to $183 million, translating to $2.30 per diluted share, a significant 30.7% increase compared to the same period in 2024.
Key financial highlights include a revenue of $2,017.4 million for the quarter, a slight increase of 0.8% from the previous quarter. The adjusted EBITDA stood at $396 million, representing 19.6% of the revenue. Additionally, the company repurchased $250 million worth of stock and expanded its share repurchase program by $500 million.
ICON plc has updated its full-year 2025 financial guidance, with expected revenue now in the range of $7,850 to $8,150 million and adjusted diluted earnings per share projected between $13.00 and $14.00. This reflects the company’s confidence in its strategic direction and cost management efforts.
Looking ahead, ICON plc remains optimistic about its growth trajectory, driven by its innovative solutions and strong customer relationships. The company continues to navigate the challenges in the clinical development and macro-economic environments with a focus on delivering value to its stakeholders.